St George Street

St George Street Capital is a UK-based biomedical charity that operates as a virtual biotech to accelerate the development of clinical-stage medicines. The organization specializes in licensing promising drug candidates that have been deprioritized by large pharmaceutical companies, most notably AstraZeneca, and advancing them through Phase 2 proof-of-concept trials. By utilizing a lean, expert-led model, the company aims to bridge the funding gap between early research and commercial viability. Their lead programs have focused on metabolic and inflammatory conditions, including the evaluation of a glucokinase activator for COVID-19 and diabetic complications. St George Street Capital reinvests any potential profits back into further medical research to benefit patients.